Skip to main content
Fig. 3 | BMC Pulmonary Medicine

Fig. 3

From: Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study

Fig. 3

Kaplan–Meier Curves for OS. The median OS was 28.3 months (range, 3.6–36.2 months) in the erlotinib group and 25.0 months (range, 3.3–36.3 months) in the gefitinib group. There was a statistically significant difference in OS between groups. *The hazard ratio was calculated using the Cox proportional hazards model, with age, sex and time span of smoking history as covariates and gefitinib/erlotinib therapy as the time-dependent factor. With respect to the OS, the results were analysed using the log-rank test (p = 0.033)

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us